

NEW TREATMENT OPTIONS FOR PATIENTS WITH MULTIPLE MYELOMA.

Alexandra Jungová

Haematology and oncology department of the
University Hospital Pilsen, Czech Republic

Introduction: Multiple myeloma is a malignant haematological malignancy with poor prognosis. Over the past 15 years there has been a significant change in treatment strategy that led to the extension of the average survival rate up to double. In the era of so-called "New" drugs are the treatment options improved significantly and at the same time increased comfort care for patients (convenient outpatient regimen, fewer side effects on the gastrointestinal tract etc.). The basic "new" drugs include thalidomide, bortezomib and lenalidomide. Each of these drugs has its unique place in the treatment of patients with multiple myeloma, on the other hand, each of these drugs has its own specific side effects. The effort planned presentation is a summary of the general strategy of treatment, compared to 3 essential medicines of a new era, including the mechanism of their effects and their side effects. The last part is planned introduction of new treatment options such as monoclonal antibodies etc.

Summary: General strategy for the treatment of patients with multiple myeloma, evaluating existing treatment with thalidomide, lenalidomide and bortezomib, compared to their adverse effects and an outline of possible future therapy (monoclonal antibodies ...)